A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Clinical trial NCT06295809 · TERMINATED

Trial details

NCT number: NCT06295809
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Carcinoma, Squamous Cell Skin Neoplasms

Start date: 2024-04-18
Primary completion: 2026-03-05
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.